Fig. 15.1 Metabolism of purine nucleotides 15.2 Forodesine Forodesine [BCX-1777, immucillin-H, 7-[(2S,3S,4R,5R)-3,4-dihydroxy-5-hydroxymethyl-2-pyrrolidinyl]-1,5-dihydro-4H-pyrrolo-[3,2-d]-pyrimidin-4-one, monohydrochloride] is a transition-state analog that potently inhibits PNP enzyme activity (Fig. 15.2) [12–15]. Forodesine has shown anticancer…
Fig. 5.1 Chimeric structure of rituximab. Rituximab is a chimeric anti-CD20 monoclonal antibody containing human IgG1 heavy chain and human kappa light chain constant regions and murine immunoglobulin heavy and…
Fig. 14.1 The chemical structures of nelarabine and ara-G. (a) Nelarabine. (b) Ara-G 14.2 Mechanisms of Action 14.2.1 Mechanisms of Action (Fig. 14.2) In the blood, nelarabine is rapidly demethoxylated…
Fig. 8.1 Blinatumomab has anti-CD19 single-chain Fv (scFv) fragment at N-terminal and anti-CD3 scFv fragment at C-terminal. Each scFv is composed of V light chain and V heavy chain. Each…
Fig. 20.1 Various causes of LSC development In recent years, new techniques have begun to revolutionize the diagnosis, prognosis, and classification of leukemia. More recently, the introduction of high-speed analysis…
Aza C Supportive care Crossover No. of patients % No. of patients % No. of patients % No. evaluated 99 92 49 CR 7 7* 0 0 5 10…
Reference Regimen Patients (no.) Median age (years) ORR (%) CR (%) OS Kantarjian et al. [19] Clofarabine monotherapy 112 71 46 38 41 weeks Faderl et al. [26]a Clofarabine +…
Fig. 12.1 The molecular mechanism of action of ATO in APL. ATO binds to the B2 domain of the PML moiety of the PML-RARα protein, inducing binding of UBC9 followed…
Author Year IO Dose No. of patients Response (%) Advani A 2010 Single 1.8 mg/m2 FL: 22 FL: 68 DLBCL:26 DLBCL: 15 Ogura M 2010 Single 1.8 mg/m2 FL: 10…
Related posts: Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia: Clinical Pharmacology and Therapeutic Results Clinical Use of Clofarabine for Adults and Children with Leukemia Nelarabine Rituximab and Alemtuzumab for Chronic Lymphocytic…
